|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM286155117 |
| 003 |
DE-627 |
| 005 |
20240719231910.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2018 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.201803163
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1475.xml
|
| 035 |
|
|
|a (DE-627)NLM286155117
|
| 035 |
|
|
|a (NLM)29972604
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Shen, Zheyu
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Dotted Core-Shell Nanoparticles for T1 -Weighted MRI of Tumors
|
| 264 |
|
1 |
|c 2018
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Revised 19.07.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status Publisher
|
| 520 |
|
|
|a © 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
|
| 520 |
|
|
|a Gd-based T 1 -weighted contrast agents have dominated the magnetic resonance imaging (MRI) contrast agent market for decades. Nevertheless, they are reported to be nephrotoxic and the U.S. Food and Drug Administration has issued a general warning concerning their use. In order to reduce the risk of nephrotoxicity, the MRI performance of the Gd-based T 1 -weighted contrast agents needs to be improved to allow a much lower dosage. In this study, novel dotted core-shell nanoparticles (FeGd-HN3-RGD2) with superhigh r 1 value (70.0 mM-1 s-1 ) and very low r 2 /r 1 ratio (1.98) are developed for high-contrast T 1 -weighted MRI of tumors. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and histological analyses show good biocompatibility of FeGd-HN3-RGD2. Laser scanning confocal microscopy images and flow cytometry demonstrate active targeting to integrin αv β3 positive tumors. MRI of tumors shows high tumor ΔSNR for FeGd-HN3-RGD2 (477 ± 44%), which is about 6-7-fold higher than that of Magnevist (75 ± 11%). MRI and inductively coupled plasma results further confirm that the accumulation of FeGd-HN3-RGD2 in tumors is higher than liver and spleen due to the RGD2 targeting and small hydrodynamic particle size (8.5 nm), and FeGd-HN3-RGD2 is readily cleared from the body by renal excretion
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a contrast agents
|
| 650 |
|
4 |
|a dotted core-shell nanoparticles
|
| 650 |
|
4 |
|a longitudinal relaxivity (r1)
|
| 650 |
|
4 |
|a magnetic resonance imaging
|
| 650 |
|
4 |
|a transverse relaxivity (r2)
|
| 700 |
1 |
|
|a Song, Jibin
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhou, Zijian
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yung, Bryant C
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Aronova, Maria A
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Li, Yan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Dai, Yunlu
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Fan, Wenpei
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Liu, Yijing
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Li, Zihou
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ruan, Huimin
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Leapman, Richard D
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lin, Lisen
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Niu, Gang
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chen, Xiaoyuan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wu, Aiguo
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g (2018) vom: 04. Juli, Seite e1803163
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnns
|
| 773 |
1 |
8 |
|g year:2018
|g day:04
|g month:07
|g pages:e1803163
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.201803163
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|j 2018
|b 04
|c 07
|h e1803163
|